Future developments files

We have already seen that numeric data banks exist primarily for retrospective searching. What is therefore required in those where numeric data consitute the basic file, is to record the most reliable values in the system. In other words a critical evaluation is really required, prior to input to the system. The promotion of such evaluations is an area where Codata is particularly active. Furthermore, particular values may be determined repetitively and one wishes to record only the best value. This may mean replacing a value with a later, more accurate one, so the facility to do this must be built into the system. Finally, primary data gathered from the literature may be transformed in some way or used to calculate secondary data which can also be stored. Examples are the Information Centre for Mineral Thermodynamics in Grenoble 22), which uses primary thermodynamic data to calculate other thermodynamic functions, and the Online Data Bank on Atomic and Molecular Physics at Belfast which is working on the automatic transformation and development of relations between different data sets. This last points the way towards exciting future developments in dynamic, as opposed to static, data banks. 

The corporate file is currently run on an IBM mainframe and data are stored in Chemical Abstracts Service Registry-II format. An in-house developed graphical interface program allows searching in a very friendly manner. The technology of this software package will be replaced in the near future. This file currently contains approximately 500,000 compounds. 

ChemSmart s future development plans include the utilisation of an algorithm based on the above approach which will solve the task by an efficient linkage between its compound and reaction files. ChemSmart s general design makes the implementation of such analgorithm possible. 

To a large extent, the aim of this paper has been to demonstrate how bold and daring Mendeleev s statements were in 1869. At that time, Mendeleev loved to give his thoughts free rein and he had aU faith in the successful future development of his system. He clearly believed in atoms and even played with the idea of an internal matter constituting these atoms (thus pointing to file complexity of atoms). In sharp contrast with Mendeleev s character in 1869, the more familiar and conservative Mendeleev of the post-1869 period was very sceptic about the possible existence of physical atoms (not to mention his disbelief in Prout s hypothesis and the complexity of atoms). ... 

The present article has shown that it is possible to address factual data by using both large and comprehensive collections, and a multitude of much smaller heterogeneous files correlated by a unifying set of identifiers (such as used in the ChemFinder example). These approaches are not necessarily alternatives, and may complement one another. Future developments in this field are awaited with interest, especially with respect to the development of the mechanisms of the Internet and the major online hosts in the continuing efforts to win end user acceptance. 

The Electronic Common Technical Document (eCTD) is the vision for future electronic submissions to the FDA. This specification was developed by the International Conference on Harmonization (ICH) as an open-standards solution for electronic submissions to worldwide regulatory authorities. The FDA has adopted the eCTD as the future replacement for its other e-submission guidance, although for now the older guidance is still in effect. Note that the eCTD still depends largely on submitting text documents as PDF files and submitting data sets as SAS XPORT transport format files. 

The Chemist s View. The Forum on the Future of Industrial Research, sponsored by Standard Oil Development Company, Oct. 5, 1944. [Later published in Chemical and Engineering News. 22 (Oct. 25, 1944) 1756-1760.] Kettering file 17/38. Source for Midgley s last speech, delivered by telephone. 

When the first Moss Bill was filed, its provisions were studied by the American Chemical Society Committee on Economic Status and the Committee on Patent Matters and Related Legislation. One concern was whether an official ACS position on the bill should be presented to the governing congressional committee. The ACS bodies also felt that consideration should be given to the active involvement of ACS itself in developing a program for encouraging compensation to employed inventors. It soon became apparent to the members of the two ACS Committees that the issue was more complex than appeared, and a joint subcommittee was appointed to study the entire question in depth. This subcommittee, under my chairmanship, has been active since 1972, and it made a report to its parent committees in the fall of 1974 with recommendations for future action. 

The total expenditure on the plant, after construction and start-up, should be carefully developed and recorded for the company s files, against a need on a future project - the best possible guide to an estimate of the cost of a future plant is the detailed cost of an earlier example. 

Develop IP in house, joint venture, licence or file for the future. 

Having developed some intellectual property to the level where it is open to exploitation a decision must be made about how this should be done. R D and marketing personnel will be involved in an evaluation of the product or process to see if it is suitable for development within the company. If, for a variety of reasons, the answer is no, exploitation by other means will be considered. One way could be in a joint venture with an appropriate partner. Alternatively, it is possible to license or sell the intellectual property to another company, if this fits in with the company strategy. The final option is to abandon the project at this stage and to leave the data in the company secret files, for reconsideration at some future date. These options are shown in Figure C9. 

Dimmock et al. have prepared an extensive series of semicarbazones (248-261). The lead compound among the (arylo3 )aryl semicarbazones is 4-(4 -fluoropheno3 y)benzaldehyde semicarbazone (65). Preclinical evaluations have been completed and an IND has been filed. The compound is a potent sodium channel blocker and it is planned to be developed for the treatment of neuropathic pain. Phase I clinical trials are scheduled in the near future. 

---